MXPA05005726A - Methods and compositions for inducing apoptosis in cancer cells. - Google Patents

Methods and compositions for inducing apoptosis in cancer cells.

Info

Publication number
MXPA05005726A
MXPA05005726A MXPA05005726A MXPA05005726A MXPA05005726A MX PA05005726 A MXPA05005726 A MX PA05005726A MX PA05005726 A MXPA05005726 A MX PA05005726A MX PA05005726 A MXPA05005726 A MX PA05005726A MX PA05005726 A MXPA05005726 A MX PA05005726A
Authority
MX
Mexico
Prior art keywords
cancer cells
compositions
methods
inducing apoptosis
apoptosis
Prior art date
Application number
MXPA05005726A
Other languages
Spanish (es)
Inventor
Wagner Klaus
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MXPA05005726A publication Critical patent/MXPA05005726A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
MXPA05005726A 2002-11-27 2003-11-25 Methods and compositions for inducing apoptosis in cancer cells. MXPA05005726A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42984202P 2002-11-27 2002-11-27
US44896003P 2003-02-21 2003-02-21
US49471403P 2003-08-12 2003-08-12
US50490103P 2003-09-22 2003-09-22
PCT/US2003/037940 WO2004050895A2 (en) 2002-11-27 2003-11-25 Methods and compositions for inducing apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
MXPA05005726A true MXPA05005726A (en) 2005-08-16

Family

ID=32475709

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005726A MXPA05005726A (en) 2002-11-27 2003-11-25 Methods and compositions for inducing apoptosis in cancer cells.

Country Status (17)

Country Link
US (2) US7229617B2 (en)
EP (1) EP1576179B1 (en)
JP (1) JP2006514096A (en)
KR (3) KR100915257B1 (en)
AT (1) ATE481092T1 (en)
AU (1) AU2003297579A1 (en)
BR (1) BR0316737A (en)
CA (1) CA2507077A1 (en)
CO (1) CO5640147A2 (en)
DE (1) DE60334247D1 (en)
EC (1) ECSP055818A (en)
MX (1) MXPA05005726A (en)
NO (1) NO20052922L (en)
PL (1) PL210174B1 (en)
PT (1) PT1576179E (en)
RU (1) RU2379056C2 (en)
WO (1) WO2004050895A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
PT1576179E (en) * 2002-11-27 2010-12-21 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CN1980957A (en) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 Receptor coupling agents and therapeutic uses thereof
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
CA2586987A1 (en) * 2004-11-12 2006-05-18 Massachusetts Institute Of Technology Methods and compositions for treating cellular proliferative diseases
EP1863512A1 (en) * 2005-03-24 2007-12-12 Irm, Llc Enhancing myc-dependent sensitivity of cancer to dr5 agonists
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
WO2007025231A2 (en) * 2005-08-26 2007-03-01 The Trustees Of The University Of Pennsylvania Methods using snail transcriptional repressor
CA2564872C (en) 2005-10-25 2010-12-21 Aegera Therapeutics Inc. Iap bir domain binding compounds
AU2006338198B2 (en) * 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
TWI504597B (en) * 2006-03-16 2015-10-21 Pharmascience Inc Iap bir domain binding compounds
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
NZ572836A (en) * 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
TWI389895B (en) * 2006-08-21 2013-03-21 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
AR066913A1 (en) * 2007-06-08 2009-09-23 Irm Llc METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
JP2010530870A (en) 2007-06-22 2010-09-16 エーテーツェー チューリッヒ Antiviral agent
EP2591804A3 (en) 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US20110171171A1 (en) * 2008-06-27 2011-07-14 Aegera Therapeutics, Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
WO2010033315A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
WO2010079084A2 (en) * 2008-12-18 2010-07-15 Centre National De La Recherche Scientifique - Cnrs - Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof
BR112012010698A2 (en) 2009-11-05 2016-11-29 Uab Research Foundation method for treating a subject with cancer, method for screening a breast cancer cell, and antibody
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
RU2567544C2 (en) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir domain iap binding compounds
UY33236A (en) 2010-02-25 2011-09-30 Novartis Ag DIMERIC INHIBITORS OF THE IAP
WO2011133819A2 (en) 2010-04-21 2011-10-27 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
MY158499A (en) 2010-10-29 2016-10-14 Daiichi Sankyo Co Ltd Anti-dr5 antibodies, polynucleotides and methods
UY33794A (en) 2010-12-13 2012-07-31 Novartis Ag DIMERIC INHIBITORS OF THE IAP
US20130266590A1 (en) 2010-12-13 2013-10-10 Novartis Ag Dimeric iap inhibitors
US20140187604A1 (en) * 2011-05-03 2014-07-03 Dana-Farber Cancer Institute, Inc. Therapeutic and diagnostic target gene in acute myeloid leukemia
RU2488408C1 (en) * 2012-03-22 2013-07-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Agent and method for apoptosis induction in cancer cells
UA118028C2 (en) * 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2016209324B2 (en) 2015-01-20 2020-02-27 Igm Biosciences, Inc. Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
CN109810194B (en) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 anti-DR 5 antibody and preparation method and application thereof
CN109810193B (en) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 anti-DR 5 antibody and preparation method and application thereof
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE69128362T2 (en) 1990-06-01 1998-05-20 Chiron Corp COMPOSITIONS AND METHOD FOR IDENTIFYING MOLECULES WITH BIOLOGICAL EFFECTIVENESS
EP0758313A4 (en) 1994-05-06 1999-09-15 Pharmacopeia Inc Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AUPQ599500A0 (en) 2000-03-02 2000-03-23 Walter And Eliza Hall Institute Of Medical Research, The Novel peptides, modulatory agents therefor and methods of using them
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20020132786A1 (en) 2000-08-24 2002-09-19 Alnemri Emad S. IAP binding peptide or polypeptide and methods of using the same
IL161686A0 (en) * 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ES2357225T3 (en) * 2001-11-01 2011-04-20 Uab Research Foundation COMBINATIONS OF ANTI-DR5 ANTIBODIES AND ANTI-DR4 ANTIBODIES AND OTHER THERAPEUTIC AGENTS.
PT1576179E (en) * 2002-11-27 2010-12-21 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
EP1778879A4 (en) * 2004-06-21 2010-02-24 Univ Washington Antibodies against west nile virus and therapeutic and prophylactic uses thereof
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.

Also Published As

Publication number Publication date
ECSP055818A (en) 2006-01-27
PL210174B1 (en) 2011-12-30
JP2006514096A (en) 2006-04-27
PL377726A1 (en) 2006-02-06
RU2005120167A (en) 2006-03-10
US8173128B2 (en) 2012-05-08
EP1576179B1 (en) 2010-09-15
BR0316737A (en) 2005-12-13
EP1576179A4 (en) 2007-06-06
CO5640147A2 (en) 2006-05-31
KR100915257B1 (en) 2009-09-03
WO2004050895A2 (en) 2004-06-17
ATE481092T1 (en) 2010-10-15
AU2003297579A1 (en) 2004-06-23
PT1576179E (en) 2010-12-21
CA2507077A1 (en) 2004-06-17
EP1576179A2 (en) 2005-09-21
KR20070122578A (en) 2007-12-31
RU2379056C2 (en) 2010-01-20
US7229617B2 (en) 2007-06-12
US20050079172A1 (en) 2005-04-14
KR20050094811A (en) 2005-09-28
KR20090046973A (en) 2009-05-11
WO2004050895A3 (en) 2005-12-08
DE60334247D1 (en) 2010-10-28
US20070128204A1 (en) 2007-06-07
NO20052922D0 (en) 2005-06-15
NO20052922L (en) 2005-08-17

Similar Documents

Publication Publication Date Title
MXPA05005726A (en) Methods and compositions for inducing apoptosis in cancer cells.
TW200501960A (en) Synergistic kits and compositions for treating cancer
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
TW200612918A (en) Lonidamine analogs
TW200510413A (en) Novel pyrrolodihydroisoquinolines
AR048819A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL184617A (en) Anti-dr5 antibody comprising mutations in the heavy and light chain of full- length antibody 16e2 and various aspects associated therewith
WO2007061874A3 (en) Methods and compositions for use in treating cancer
WO2004034990A3 (en) Methods and compositions for use in treating cancer
ATE444309T1 (en) IMMUNOTHERAPY FOR CRONIC MYELOCYTIC LEUKEMIA WITH NAKED ANTI-NCA-90 ANTIBODIES
AR046184A1 (en) NUTRITIONAL COMPOSITION AGAINST COLLATERAL EFFECTS OF CHEMOTHERAPY AND RADIOTHERAPY
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
MX2009005058A (en) Methods of treating, diagnosing or detecting cancer.
MXPA04006572A (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections.
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
MX2009010269A (en) Methods of treating cancer by administering human il-18 combinations.
ATE469659T1 (en) STIBOGLUCONATE SODIUM AND IL-2 FOR CANCER TREATMENT
WO2006075012A3 (en) Pyrrolodihydroisoquinolines as antiproliferative agents
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
UY28345A1 (en) NEW COMPOUNDS
WO2005082357A8 (en) Use of beta-lapachone for treating hematologic tumors
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
TW200612917A (en) Prevention of cancer
GB2461615A (en) Assay devices and methods and components for use therein
WO2006132907A3 (en) Methods of treating, diagnosing or detecting cancer using an ephb3 modulator

Legal Events

Date Code Title Description
FG Grant or registration